Modification of acyl-plasmin-streptokinase complex with polyethylene glycol. Reduction of sensitivity to neutralizing antibody.
Acyl-plasmin-streptokinase complex has advantages as a 'site' directed fibrinolytic agent with the active site protected from the plasma protease inhibitors. But, in clinical use, the fibrinolytic potential of this acyl-enzyme complex is modified or abolished by the presence of streptokinase antibodies in the patients. Therefore, better therapeutic agents are required. In this work, chemical modification of the acyl-plasmin-streptokinase complex with polyethylene glycol was found to result in marked resistance to neutralization with streptokinase antibodies.
Tomiya
N
N
Watanabe
K
K
Awaya
J
J
Kurono
M
M
Fujii
S
S
D000906:Antibodies; D001565:Benzoates; D005341:Fibrinolysin; D010960:Plasminogen Activators / Q000378:metabolism; D011092:Polyethylene Glycols; D013300:Streptokinase / Q000276:immunology*
D000906:Antibodies; D001565:Benzoates; C002238:4-nitrophenyl 4'-guanidinobenzoate; D011092:Polyethylene Glycols; C028210:monomethoxypolyethylene glycol; D013300:Streptokinase; D010960:Plasminogen Activators; D005341:Fibrinolysin